Influenza virus split vaccine

After vaccination with the influenza split vaccine, the body forms humoral antibodies against the hemagglutinin and neuraminidase surface antigens, which is why the antibodies can neutralize the influenza virus. Concentrations of protective antibodies are usually achieved within 2-3 weeks. The duration of immunity generated by the vaccine against the same or similar strains of the vaccine varies, usually 6-12 months. The protection provided by the influenza split vaccine is only against infection with the influenza virus and does not work against colds (flu-like infections) caused by other pathogens, etc.

Vaccination target: Influenza split vaccine is recommended for adults and children over 6 months old to prevent influenza. This product is especially recommended for the following groups: - People over 60 years old. - People with cardiovascular diseases, metabolic diseases (diabetes), cystic fibrosis, chronic respiratory diseases and chronic renal insufficiency. - Patients with congenital or acquired immunodeficiency or deficiency. - People living in nursing homes or sanatoriums. This product is also recommended for people whose occupational risk of infection increases, such as medical staff.

Dosage Adults and children over 3 years old, adolescents: 1 vaccination, 0.5 ml injection. Children 6 months to 3 years old: 1 vaccination, 0.25 ml injection. Children who have not been vaccinated before should be vaccinated twice, 4 weeks apart. Influenza split vaccine should be administered before the start of the influenza season or as needed by epidemiology. Appropriate doses or updated antigen components should be repeated every year according to age. Injection method Influenza split vaccine is used for intramuscular or subcutaneous injection. Patients with thrombocytopenia or other bleeding disorders should be vaccinated subcutaneously, as intramuscular injection may cause bleeding in these patients. Influenza split vaccine cannot be administered intravenously under any circumstances. Before injection, the device should be inspected visually for foreign matter and/or changes in physical shape. The device should be shaken before use.

People who are known to be allergic to one or more components of the vaccine (including the active ingredients and excipients of the vaccine (see below)) cannot be vaccinated, especially those who are hypersensitive to egg protein. In the case of high fever or acute infection, it is recommended to be vaccinated after the body temperature has returned to normal for 2 weeks.

No time interval is required between this vaccine and other vaccines. If completely different vaccines need to be administered at the same time, different injection sites should be selected. After influenza vaccination, false positive results may be observed when serum blood tests for anti-HIV1 antibodies, anti-hepatitis C antibodies, and especially anti-HTLV1 antibodies are performed using the ELISA method. The Western Blot method can prove that the result is wrong. This temporary false positive result may be caused by an IgM reaction caused by vaccination.

If the vaccine is stored at +2°C to +8°C, it is valid for 12 months. To protect the vaccine from light, it should be kept in its original packaging. The vaccine should be kept out of the reach of children.

0.5ml/vial